Advertisement

Perioperative and Hypertensive Crisis Management of Pheochromocytomas

  • Becky Thai MuldoonEmail author
  • Kevin F. Brown
  • Diane U. Elegino-Steffens
Chapter

Abstract

With its rarity, non-specific symptoms, and paroxysmal nature, pheochromocytomas can be difficult to diagnose without an index of suspicion. It is crucial that pheochromocytomas are recognized early so that appropriate medical and surgical management can be initiated to avoid pheochromocytoma/hypertensive crises due to catecholamine-induced hemodynamic instability causing end-organ damage. With proper preoperative management with alpha-adrenergic blockade and postoperative monitoring and treatment in the critical care setting, perioperative mortality in pheochromocytoma resections has decreased dramatically since the 1950s.

Keywords

Pheochromocytoma Hypertensive crisis Adrenal adenoma Pheochromocytoma crisis Phenoxybenzamine Alpha-blockade 

References

  1. 1.
    Amar L, Eisenhofer G. Diagnosing phaeochromocytoma/paraganglioma in a patient presenting with critical illness: biochemistry versus imaging. Clin Endocrinol. 2015;83(3):298–302.CrossRefGoogle Scholar
  2. 2.
    Amar L, Fassnacht M, Gimenez-Roqueplo AP, Januszewicz A, Prejbisz A, Timmers H, Plouin PF. Long-term postoperative follow-up in patients with apparently benign pheochromocytoma and paraganglioma. Horm Metab Res. 2012;44(05):385–9.PubMedCrossRefGoogle Scholar
  3. 3.
    Amar L, Servais A, Gimenez-Roqueplo AP, Zinzindohoue F, Chatellier G, Plouin PF. Year of diagnosis, features at presentation, and risk of recurrence in patients with pheochromocytoma or secreting paraganglioma. J Clin Endocrinol Metabol. 2005;90(4):2110–6.CrossRefGoogle Scholar
  4. 4.
    Agarwal G, Sadacharan D, Kapoor A, Batra A, Dabadghao P, Chand G, Mishra SK. Cardiovascular dysfunction and catecholamine cardiomyopathy in pheochromocytoma patients and their reversal following surgical cure: results of a prospective case-control study. Surgery. 2011;150(6):1202–11.PubMedCrossRefGoogle Scholar
  5. 5.
    Castinetti F, Kroiss A, Kumar R, Pacak K, Taieb D. 15 YEARS OF PARAGANGLIOMA: imaging and imaging-based treatment of pheochromocytoma and paraganglioma. Endocr Relat Cancer. 2015;22(4):T135–45.PubMedCrossRefGoogle Scholar
  6. 6.
    Chen H, Sippel RS, O’Dorisio MS, Vinik AI, Lloyd RV, Pacak K, et al. The north american neuroendocrine tumor society consensus guideline for the diagnosis and management of neuroendocrine tumors: Pheochromocytoma, paraganglioma, and medullary thyroid cancer. Pancreas. 2010;39(6):775–83.PubMedPubMedCentralCrossRefGoogle Scholar
  7. 7.
    Chew SL. Recent developments in the therapy of pheochromocytomas and paragangliomas. Ann N Y Acad Sci. 2004;1073:405–16.Google Scholar
  8. 8.
    Chao A, Yeh YC, Yen TS, Chen YS. Phaeochromocytoma crisis–a rare indication for extracorporeal membrane oxygenation. Anaesthesia. 2008;63(1):86–8.PubMedCrossRefGoogle Scholar
  9. 9.
    Eisenhofer G, Pacak K, Maher ER, Young WF, de Krijger RR. Pheochromocytoma. Clin Chem. 2013;59(3):466–72.PubMedCrossRefGoogle Scholar
  10. 10.
    Falhammar H, Kjellman M, Calissendorff J. Initial clinical presentation and spectrum of pheochromocytoma: a study of 94 cases from a single center. Endocr Connect. 2018;7(1):186–92.PubMedCrossRefGoogle Scholar
  11. 11.
    Fassnacht M, Arlt W, Bancos I, Dralle H, Newell-Price J, Sahdev A, et al. Management of adrenal incidentalomas: European society of endocrinology clinical practice guideline in collaboration with the European network for the study of adrenal tumors. Eur J Endocrinol. 2016;175(2):G1–G34.PubMedCrossRefGoogle Scholar
  12. 12.
    Gagnon N, Mansour S, Bitton Y, Bourdeau I. Takotsubo-like cardiomyopathy in a large cohort of patients with pheochromocytoma and paraganglioma. Endocr Pract. 2017;23(10):1178–92.PubMedCrossRefGoogle Scholar
  13. 13.
    Guerrero MA, Schreinemakers JM, Vriens MR. Clinical spectrum of pheochromocytoma. J Am Coll Surg. 2009;209:727–32.PubMedCrossRefGoogle Scholar
  14. 14.
    Hana NN, Kenady DE. Pheochromocytoma. In: Holzhemier RG, Mannick JA, editors. Surgical treatment: evidence-based and problem-oriented. Munich: Zuckschewerdt; 2001.Google Scholar
  15. 15.
    Hariskov S, Schumann R. Intraoperative management of patients with incidental catecholamine producing tumors: a literature review and analysis. J Anaesthesiol Clin Pharmacol. 2013;29(1):41–6.PubMedPubMedCentralCrossRefGoogle Scholar
  16. 16.
    Hoffman BB. Catecholamines, sympathomimetic drugs and adrenergic receptor antagonists. In: Goodman & Gillman’s the pharmacological basis of therapeutics. Philadelphia: McGraw-Hill; 2001. p. 215–68.Google Scholar
  17. 17.
    Janssen I, Chen CC, Millo CM, Ling A, Taieb D, Lin FI, et al. PET/CT comparing (68)ga-DOTATATE and other radiopharmaceuticals and in comparison with CT/MRI for the localization of sporadic metastatic pheochromocytoma and paraganglioma. Eur J Nucl Med Mol Imaging. 2016;43(10):1784–91.PubMedCrossRefGoogle Scholar
  18. 18.
    Kakoki K, Miyata Y, Shida Y, et al. Pheochromocytoma multisystem crisis treated with emergency surgery: a case report and literature review. BMC Res Notes. 2015;8:758.PubMedPubMedCentralCrossRefGoogle Scholar
  19. 19.
    Kinney MA, Narr BJ, Warner MA. Perioperative management of pheochromocytoma. J Cardiothorac Vasc Anesth. 2002;16(3):359–69.PubMedCrossRefGoogle Scholar
  20. 20.
    Kobayashi T, Iwai A, Takahashi R, Ide Y, Nishizawa K, Mitsumori K. Spontaneous rupture of adrenal pheochromocytoma: review and analysis of prognostic factors. J Surg Oncol. 2005;90:31–5.PubMedCrossRefGoogle Scholar
  21. 21.
    Kopetschke R, Slisko M, Kilisli A, Tuschy U, Wallaschofski H, Fassnacht M, et al. Frequent incidental discovery of phaeochromocytoma: data from a German cohort of 201 phaeochromocytoma. Eur J Endocrinol. 2009;161(2):355–61.PubMedCrossRefGoogle Scholar
  22. 22.
    Kwon SY, Lee KS, Lee JN, Ha YS, Choi SH, Kim HT, Kwon TG. Risk factors for hypertensive attack during pheochromocytoma resection. Investig Clin Urol. 2016;57(3):184–90.PubMedPubMedCentralCrossRefGoogle Scholar
  23. 23.
    Lebuffe G, Dosseh ED, Tek G, Tytgat H, Moreno S, Travernier B, Vallet B, Proye CA. The effect of calcium channel blockers on outcome following the surgical treatment of phaeochromocytomas and paragangliomas. Anesthesia. 2005;60(5):439.CrossRefGoogle Scholar
  24. 24.
    Lenders JW, Duh QY, Eisenhofer G, Gimenez-Roqueplo AP, Grebe SK, Murad MH, et al. Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2014;99(6):1915–42.PubMedCrossRefGoogle Scholar
  25. 25.
    Lenders JWM, Eisenhofer G. Update on modern management of pheochromocytoma and paraganglioma. Endocrinol Metab (Seoul, Korea). 2017;32(2):152–61.CrossRefGoogle Scholar
  26. 26.
    Lentschener C, Gaujoux S, Tesniere A, Dousset B. Point of controversy: perioperative care of patients undergoing pheochromocytoma removal-time for a reappraisal? Eur J Endocrinol. 2011;165:365–73.PubMedCrossRefGoogle Scholar
  27. 27.
    Martucci VL, Pacak K. Pheochromocytoma and paraganglioma: diagnosis, genetics, management, and treatment. Curr Probl Cancer. 2014;38(1):7–41.PubMedPubMedCentralCrossRefGoogle Scholar
  28. 28.
    Mazza A, Armigliato M, Marzola MC, Schiavon L, Montemurro D, Vescovo G, et al. Anti-hypertensive treatment in pheochromocytoma and paraganglioma: current management and therapeutic features. Endocrine. 2014;45(3):469–78.PubMedCrossRefGoogle Scholar
  29. 29.
    Meune C, Bertherat J, Dousset B, Jude N, Bertagna X, Duboc D, Weber S. Reduced myocardial contractility assessed by tissue Doppler echocardiography is associated with increased risk during adrenal surgery of patients with pheochromocytoma: report of a preliminary study. J Am Soc Echocardiogr. 2006;19(12):1466–70.PubMedCrossRefGoogle Scholar
  30. 30.
    Muratori D, Pedrotti P, Baroni M, Belloni A, Quattrocchi G, Milazzo A, Giannattasio C, Roghi A. Catecholamine-induced myocarditis in pheochromocytoma. G Ital Cardiol (2006). 2017;18(2):164-8.Google Scholar
  31. 31.
    Pacak K. Preoperative management of the pheochromocytoma patient. J Clin Endocrinol Metab. 2007;92(11):4069–79.PubMedCrossRefGoogle Scholar
  32. 32.
    Ramachandran R, Rewari V. Current perioperative management of pheochromocytomas. Indian J Urol. 2017;33(1):19–25.PubMedPubMedCentralGoogle Scholar
  33. 33.
    Randle RW, Balentine CJ, Pitt SC, Schneider DF, Sippel RS. Selective versus non-selective alpha-blockade prior to laparoscopic adrenalectomy for pheochromocytoma. Ann Surg Oncol. 2017;24(1):244–50.PubMedCrossRefGoogle Scholar
  34. 34.
    Riester A, Weismann D, Quinkler M, Lichtenauer UD, Sommerey S, Halbritter R, et al. Life-threatening events in patients with pheochromocytoma. Eur J Endocrinol. 2015;173(6):757–64.PubMedCrossRefGoogle Scholar
  35. 35.
    Ritter S, Guertler T, Meier CA, Genoni M. Cardiogenic shock due to pheochromocytoma rescued by extracorporeal membrane oxygenation. Interact Cardiovasc Thorac Surg. 2011;13(1):112–3.PubMedCrossRefGoogle Scholar
  36. 36.
    Sakamoto K, Kojima S, Hokimoto S, Ogawa H. Pheochromocytoma multisystem crisis with transient stress cardiomyopathy due to ruptured pheochromocytoma. BMJ Case Rep. 2015;2015:bcr2015212456.PubMedPubMedCentralCrossRefGoogle Scholar
  37. 37.
    Scholten A, Cisco RM, Vriens MR, et al. Pheochromocytoma crisis is not a surgical emergency. J Clin Endocrinol Metab. 2013;98:581–91.PubMedCrossRefGoogle Scholar
  38. 38.
    Scholten A, Vriens MR, Cromheecke G, Rinkes IHB, Valk GD. Hemodynamic instability during resection of pheochromocytoma in MEN versus non-MEN patients. Eur J Endocrinol. 2011;165(1):91–6. EJE-11.PubMedCrossRefGoogle Scholar
  39. 39.
    Shao Y, Chen R, Shen ZJ, Teng Y, Huang P, Rui WB, et al. Preoperative alpha blockade for normotensive pheochromocytoma: is it necessary? J Hypertens. 2011;29(12):2429–32.PubMedCrossRefGoogle Scholar
  40. 40.
    Smet M, Convens C, Verhelst J. Successful use of an intra-aortic balloon pump in an acute phaeochromocytoma crisis with severe catecholamine cardiomyopathy. Clin Intensive Care. 1998;9(4):167–9.CrossRefGoogle Scholar
  41. 41.
    Steinsapir J, Carr AA, Prisant LM, Bransome ED Jr. Metyrosine and pheochromocytoma. Arch Intern Med. 1997;157(8):901–6.PubMedCrossRefGoogle Scholar
  42. 42.
    Streeten DH, Anderson GH. Mechanisms of orthostatic hypotension and tachycardia in patients with pheochromocytoma. Am J Hypertens. 1996;9(8):760–9.PubMedCrossRefGoogle Scholar
  43. 43.
    Thanapaalasingham K, Pollmann AS, Schelew B. Failure of metyrosine therapy for preoperative management of pheochromocytoma: a case report. Can J Anaesth. 2015;62(12):1303–7.PubMedCrossRefGoogle Scholar
  44. 44.
    Uchida N, Ishiguro K, Suda T, et al. Pheochromocy-toma multisystem crisis successfully treated by emergency surgery: report of a case. Surg Today. 2010;40:990–6.PubMedCrossRefGoogle Scholar
  45. 45.
    van der Zee PA, de Boer A. Pheochromocytoma: a review on preoperative treatment with phenoxybenzamine or doxazosin. Neth J Med. 2014;72(4):190–201.PubMedGoogle Scholar
  46. 46.
    Wachtel H, Kennedy EH, Zaheer S, Bartlett EK, Fishbein L, Roses RE, et al. Preoperative metyrosine improves cardiovascular outcomes for patients undergoing surgery for pheochromocytoma and paraganglioma. Ann Surg Oncol. 2015;22(Suppl 3):S646–54.PubMedCrossRefGoogle Scholar
  47. 47.
    Whitelaw BC, Prague JK, Mustafa OG, et al. Phaeochromocytoma crisis. Clin Endocrinol. 2014;80:13–22.CrossRefGoogle Scholar
  48. 48.
    Wu S, Chen W, Shen L, Xu L, Zhu A, Huang Y. Risk factors for prolonged hypotension in patients with pheochromocytoma undergoing laparoscopic adrenalectomy: a single-center retrospective study. Sci Rep. 2017;7(1):5897.PubMedPubMedCentralCrossRefGoogle Scholar
  49. 49.
    Young WF Jr. Management approaches to adrenal incidentalomas. A view from Rochester, Minnesota. Endocrinol Metab Clin N Am. 2000;29(1):159–85, x.CrossRefGoogle Scholar
  50. 50.
    Young WF Jr. Clinical practice. The incidentally discovered adrenal mass. N Engl J Med. 2007;356(6):601–10.PubMedCrossRefGoogle Scholar
  51. 51.
    Zeiger MA, Thompson GB, Duh QY, Hamrahian AH, Angelos P, Elaraj D, et al. American association of clinical endocrinologists and american association of endocrine surgeons medical guidelines for the management of adrenal incidentalomas: executive summary of recommendations. Endocr Pract. 2009;15(5):450–3.PubMedCrossRefGoogle Scholar
  52. 52.
    Zhou X, Liu D, Su L, Long Y, Du W, Miao Q, Huang Y. Pheochromocytoma crisis with severe cyclic blood pressure fluctuations in a cardiac Pheochromocytoma patient successfully resuscitated by extracorporeal membrane oxygenation: a case report. Medicine. 2015;94(17):e790.PubMedPubMedCentralCrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Becky Thai Muldoon
    • 1
    Email author
  • Kevin F. Brown
    • 2
  • Diane U. Elegino-Steffens
    • 1
  1. 1.Department of Medicine, Section of EndocrinologyTripler Army Medical CenterHonoluluUSA
  2. 2.Department of MedicineTripler Army Medical CenterHonoluluUSA

Personalised recommendations